| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ACR Convergence 2021
|
Brooks, Helen
|
|
|
4 |
1 |
p. e18-e19
|
artikel
|
| 2 |
Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials
|
Stamp, Lisa K
|
|
|
4 |
1 |
p. e53-e60
|
artikel
|
| 3 |
“Aun con dolor, hay que trabajar.”
|
Astudillo, Olaya
|
|
|
4 |
1 |
p. e23
|
artikel
|
| 4 |
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
|
Felten, Renaud
|
|
|
4 |
1 |
p. e13-e16
|
artikel
|
| 5 |
Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry
|
Seror, Raphaèle
|
|
|
4 |
1 |
p. e8-e11
|
artikel
|
| 6 |
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
|
Schmiedeberg, Kristin
|
|
|
4 |
1 |
p. e11-e13
|
artikel
|
| 7 |
“Even in pain, you have to work.”
|
Astudillo, Olaya
|
|
|
4 |
1 |
p. e22
|
artikel
|
| 8 |
FDA approves avacopan for ANCA-associated vasculitis
|
Thorley, Jennifer
|
|
|
4 |
1 |
p. e21
|
artikel
|
| 9 |
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
|
Mahil, Satveer K
|
|
|
4 |
1 |
p. e42-e52
|
artikel
|
| 10 |
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis
|
Boekel, Laura
|
|
|
4 |
1 |
p. e5-e7
|
artikel
|
| 11 |
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
|
Andersen, Kathleen M
|
|
|
4 |
1 |
p. e33-e41
|
artikel
|
| 12 |
Research in Brief
|
Thorley, Jennifer
|
|
|
4 |
1 |
p. e20
|
artikel
|
| 13 |
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
|
|
|
|
4 |
1 |
p. e24-e32
|
artikel
|
| 14 |
Socioeconomic vulnerability and rheumatoid arthritis in the Philippines
|
Robredo, Janine Patricia G
|
|
|
4 |
1 |
p. e17
|
artikel
|
| 15 |
Telemedicine: is the new normal fit for purpose?
|
The Lancet Rheumatology,
|
|
|
4 |
1 |
p. e1
|
artikel
|
| 16 |
The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease
|
Cooles, Faye A H
|
|
|
4 |
1 |
p. e61-e72
|
artikel
|
| 17 |
Uricaemia as a surrogate endpoint in gout trials and the treat-to-target approach for gout management
|
Bardin, Thomas
|
|
|
4 |
1 |
p. e7-e8
|
artikel
|
| 18 |
What does endemic COVID-19 mean for the future of rituximab?
|
Liew, David F L
|
|
|
4 |
1 |
p. e3-e5
|
artikel
|
| 19 |
Who, what, and when—effective therapy for severe COVID-19
|
Kelmenson, Daniel A
|
|
|
4 |
1 |
p. e2-e3
|
artikel
|
Tijdschrift beschrijving